BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.73B |
| Revenue (ttm) | 79.14M |
| Net Income (ttm) | -214.09M |
| Shares Out | 178.13M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,854,651 |
| Open | 15.40 |
| Previous Close | 15.39 |
| Day's Range | 15.18 - 15.46 |
| 52-Week Range | 3.30 - 18.48 |
| Beta | 2.58 |
| Analysts | Buy |
| Price Target | 21.27 (+38.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial ...
Financial Performance
In 2020, BCRX's revenue was $17.81 million, a decrease of -63.53% compared to the previous year's $48.84 million. Losses were -$182.81 million, 67.9% more than in 2019.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 21.27, which is an increase of 38.39% from the latest price.
News
BioCryst to Present at 2021 Cantor Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conferen...
NICE Recommends BioCryst's Hereditary Angioedema Med
The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recommendat...
NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Pa...
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's (UK) National Institute for Health and Care Excel...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Virtual Wells Fargo Healthcare Con...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 18...
US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Rapivab (peramivir injection) The ...
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to ...
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised i...
BioCryst Appoints Dr. Steven Galson to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Admi...
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accepted ...
2 Soaring Biotech Stocks With More Fuel in the Tank
These recent winners still have a long way to run.
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says that it is well-capitalized, with cash, cash...
BioCryst Withdraws Public Offering
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it has withdrawn its proposed public offering. With our strong balance ...
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $200 million of its common stock and, in lieu of...
Why BioCryst Pharmaceuticals Rose 8% on Thursday
The company's first commercial drug launch keeps exceeding expectations.
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of $50 million, with $28.5 mill...
3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
BioCryst to Report Second Quarter 2021 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Th...
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturn...
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients wit...
RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its ...
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks pat...
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from ...
—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO— —Multiple data prese...
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid C...
RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and ...
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
There's more than one opportunity for it to do so.
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Isr...
— Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel — — Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel —